3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Interventions
Paclitaxel
12
Carboplatin
11
Cisplatin
9
Letrozole
6
Drug Therapy
6
liposomal doxorubicin
5
Megestrol Acetate
4
Bevacizumab
4
spartalizumab
3
Topotecan
3
Taxes
3
Medroxyprogesterone Acetate
3
olaparib
2
niraparib
2
atezolizumab
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Imiquimod
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Doxorubicin
2
1-dodecylpyridoxal
2
trametinib
1
sintilimab
1
saracatinib
1
ricin A-GnRH conjugate
1
pertuzumab
1
pembrolizumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
pertuzumab
×
Gynecologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled